Robert Miller on aspirin to reduce the risk of recurrence
Robert Miller, Chief Medical Science Officer at CancerLinQ shared on LinkedIn:
“When I was in practice, I had a number of patients with curatively-treated early stage breast cancer ask if they should take a daily aspirin to reduce the risk of recurrence, based on a number of observational studies and at least 1 meta-analysis suggesting improved disease-free survival.
Given the lack of definitive evidence, I usually said I did not advise it. An additional consideration was the small risk of a serious Gastrointestinal or CNS bleeding complication. This interventional study that came out yesterday in JAMA seems to confirm a lack of benefit with ASA, as invasive disease–free survival events, including death, invasive progression (both distant and locoregional), and new primary events were numerically HIGHER in the aspirin group – yikes (although not statistically significant).
Disappointing, but this is why we need randomized, prospective trials for many questions…”
Further Reading.
Source: Robert Miller/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023